Year Partnered with Savant: 2023
Sector: Med-tech
Industry: Advanced diagnosis
Product: AI Diagnostics uses a proprietary digital stethoscope to record breath sounds that feed into the AI-driven app to determine whether or not the breath sounds represent a TB risk.
Market Size: (Local) ZAR 18.63 billion (Global) USD 5.1 billion
Differentiation: Very large, proprietary lung sound database, consumable free and unique hardware.
Investment Stage: Seed
Stage: Venture & Grow Locally
Founding Team: Braden Van Breda, Mark Van Breda, Johan Coetzee
AI Diagnostics
About AI Diagnostics
AI Diagnostics has developed an innovative Tuberculosis (TB) screening system that utilizes artificial intelligence to analyse lung sounds. This system comprises a proprietary digital stethoscope integrated with an intuitive AI Diagnostics App, that guides users through data collection. A key advantage is its enhanced detection accuracy compared to the currently adopted 4-symptom questionnaire, significantly reducing missed TB-positive and false-positive cases, thus lowering overall diagnosis costs.
The system’s customizability allows for a scalar prediction output, offering flexibility in configuring decision thresholds based on specific environments or applications. The consumable-free nature of the solution eliminates the need for disposable components, addressing logistical challenges associated with the storage, distribution, and safe disposal of consumables.
Value Proposition
AI Diagnostics redefines TB screening, providing a streamlined and efficient solution for diverse healthcare settings. This solution stands out as the most fitting choice for clinic and infield screening environments, combining affordability, efficiency, and accuracy. By meeting all key criteria specified by the World Health Organization (WHO), AI Diagnostics ensures a reliable and accessible tool for the critical task of identifying individuals at risk of TB. Additionally, the consumable-free design nature of AI Diagnostics solution offers flexibility and eliminates logistical challenges associated with disposable components.
Team
Braden van Breda
Braden is a Biomedical Engineer with a five-year professional history. He was previously Lead Engineer at Strait Access Technologies where he developed cardiovascular devices. As CEO, Braden leverages his biomedical engineering background to drive innovation and spearhead AI Diagnostics.
Mark Van Breda (COO)
Mark Van Breda is an Electrical Engineer and a serial entrepreneur. Over the years, he has demonstrated a keen ability to navigate the complexities of different industries, ensuring operational excellence, efficiency, and the achievement of strategic goals.
Johan Coetzee (CTO)
Johan is a Senior Data Scientist with a strong foundation in biomedical engineering, he brings an impressive track record of successfully delivering end-to-end data science products across diverse sectors.
